Prospective Study on Treatment Outcomes and Quality of Life Improvement in Lymphedema and Other Lymphatic Disorders

Prospective Study on Treatment Outcomes and Quality of Life Improvement in Lymphedema and Other Lymphatic Disorders - Prospective Study on Treatment Outcomes and Quality of Life Improvement in Lymphedema and Other Lymphatic Disorders

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000058749

Enrollment

1000

Registered

2025-08-09

Start date

2025-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lymphedema and Other Lymphatic Disorders

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who visited the outpatient clinic of Mukumi Clinic between April 1, 2025, and March 31, 2030, and were diagnosed with lymphedema or other lymphatic disorders, who meet the following conditions: Provided signed consent regarding academic presentations and publications at the time of the first visit to Mukumi Clinic or equivalent. Underwent examination, treatment, or surgery at Mukumi Clinic during the study period.

Exclusion criteria

Exclusion criteria: Patients deemed unsuitable for inclusion in the study by the principal investigator. Patients who declined to participate in the study.

Design outcomes

Primary

Measure	Time frame
Changes in clinical symptoms and anthropometric measurements before and after treatment (e.g., limb circumference, severity of edema, skin changes)	—

Secondary

Measure	Time frame
Changes in quality of life (QOL) scores, assessed by standardized questionnaires such as the Lymphedema Quality of Life Inventory or SF-36 Changes in functional status (e.g., activities of daily living [ADL] scores, patient-reported outcomes) Incidence of complications such as cellulitis Changes in imaging findings (e.g., lymphangiography, lymphoscintigraphy) Recurrence rates and need for additional treatment during follow-up Domain-specific QOL analysis (physical, mental, and social functioning) Exploratory analyses using other clinically relevant parameters obtainable from medical records and patient questionnaires	—

Measure

Time frame

Changes in quality of life (QOL) scores, assessed by standardized questionnaires such as the Lymphedema Quality of Life Inventory or SF-36 Changes in functional status (e.g., activities of daily living [ADL] scores, patient-reported outcomes) Incidence of complications such as cellulitis Changes in imaging findings (e.g., lymphangiography, lymphoscintigraphy) Recurrence rates and need for additional treatment during follow-up Domain-specific QOL analysis (physical, mental, and social functioning) Exploratory analyses using other clinically relevant parameters obtainable from medical records and patient questionnaires

—

Countries

Japan

Contacts

Public ContactMakoto Mihara

Mukumi Clinin Clinical Department

mihara.plasticsurgery@gmail.com050-3146-4579

Outcome results